The ability of isorhamnetin to suppress hypoxia‐induced autophagy and tumor growth in GC through PI3K/AKT/mTOR inhibition displays its potential as a therapeutic agent in hypoxic tumor environments. The gene discussed is PIK3CG; the disease is gastric cancer.